Compare Neurocrine Biosciences Inc (NBIX) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PPG Industries, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while PPG Industries, Inc. trades at $107.4 (market cap $24.39B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.7% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PPG | |
|---|---|---|
Market Cap | $15.77B | $24.39B |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $131.56 |
52-Week Low | $123.10 | $94.34 |
Enterprise Value | $15.78B | $30.26B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PPG Industries trades at $109.72, down 2.5% today, with a bearish technical signal and mixed earnings history. The stock shows solid fundamentals with a P/E of 15.74, net income margin of 9.57%, and a consensus analyst price target of $129.17. Recent news highlights product innovations like the ONE RANGE marine coatings and leadership changes aimed at growth. Cash flow improved in 2025 to $893M net, though 2026 projections show a slight decline.
The outlook is cautiously optimistic, supported by analyst buy ratings (55%) and strong profitability metrics, but risks include volatile earnings performance and economic sensitivity. Near-term resistance at $111 and support at $109 are key levels to watch amid current bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
